β-adrenergic receptor signaling in cardiac function and heart failure

McGill Journal of Medicine

Volumn 10, Issue 2, 2007, Pages 99-104

  Madamanchi, Aasakiran ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 4 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL L TYPE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN HEAVY CHAIN ALPHA; PHOSDUCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; RAC PROTEIN; RECEPTOR SUBTYPE; RHO FACTOR; UNCLASSIFIED DRUG;

CONFORMATIONAL TRANSITION; DETERIORATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE FUNCTION; HUMAN; INTERNALIZATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 41149129769     PISSN: 1201026X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Heart and stroke statistical update. Dallas, Tx: American Heart Association; 2001.
2. Leimbach WN, Wallin G, Victor RG, et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 93: 720-729.
3. Koch WJ.Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Molecular and Cellular Biochemistry 2004; 263: 5-9.
4. Vassilatis DK, Hohmann JG ,Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 2003; 100: 4903-8.
5. WessJ. G-protein-coupled receptors:molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 1997; 11:346-354.
6. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE 2001:RE15.
7. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathetic drugs, and adrenergic receptor anatagonists. In: Hardman J, Limbird L, editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:199-248.
8. Freedman NJ, Lefkowitz RJ.Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004; 113: 1379-82.
9. Pavoine C, Defer N. The cardiac beta2-adrenergic: signaling a new role for the cPLA2. Cell Signal 2005: 17:141-152.
10. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacology Rev 2001; 53:1-24.
11. Barak LS, Arabic K, Fang X, et al. Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor. .J Biol Chem 1999; 274:7565-7569.
12. Freedman NJ, Leggett SB, Drachmann DE, et al. Phosphorylation anddesensitization of the human beta 1adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem 1995: 270:17953-17961.
13. Perry SJ, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002; 12:130-8.
14. Claing A, Laporte SA, Caron MG, et al. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 202; 66:61-79.
15. Zhang J, Ferguson SS, Barak LS, et al. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J Biol Chem 1996; 271:18302-5.
16. Esler M, Kaye D, Lambert G, et al. Adrenergic nervous system in heart failure. Am J Cardiol 1997; 80:7L-14L.
17. Katz AM. Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle. Part II: Hypertrophy and dilatation of the failing heart. J Card Fail 1998; 4:67-81.
18. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002; 105: 85-92.
19. Rohrer DK, Desai KH, Jasper JR ,et al. Targeted disruption of the mouse beta1-adrenergic receptor gene:developmental and cardiovascular effects. Proc Natl Acad Sci U S A 1996; 93:7375-80.
20. Engelhardt S, Hein L,Wiesmann F, et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A1996; 96: 7059-64.
21. Chruscinski AJ, Rohrer DK, Schauble E, et al. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem. 1999; 274:16694-16700.
22. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994; 264: 582-6.
23. Akhter SA, Skaer CA, Kypson AP, et al. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A 1997; 94:12100-5.
24. Dorn GW 2nd, Tepe NM, Lorenz JN, et al. Low-and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A1999; 96: 6400-5.
25. Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2001; 107: 967-74.
26. Du XJ, Autelitano DJ, Dilley RJ, et al. Beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis.Circulation 2000; 101:71-77.
27. Koch WJ, Inglese J, Stone WC, et al. The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem 1993; 268:8256-60.
28. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995; 268:1350-3.
29. Jaber M, Koch WJ, Rockman H, et al. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci U S A 1996; 93:12974-9.
30. Rockman HA, Choi DJ, Akhter SA, et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 1998; 273:18180-4.
31. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998; 352 Suppl 1:SI8-14.
32. Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001; 103: 1311-6.
33. Eckhart AD, Duncan SJ, Penn RB, et al. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 2000; 86:43-50.
34. Li Z, Laugwitz KL, Pinkernell K, et al. Effects of two Gbetagamma-binding proteins-N-terminally truncated phosducin and beta-adrenergic receptor kinase C terminus (betaARKct) - in heart failure. Gene Ther 2003; 10: 1354-61.
35. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999; 274:8347-50.
36. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000; 19:2537-48.
37. Crackower MA, Oudit GY, Kozieradzki I,et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110:737-749.
38. Naga Prasad SV, Laporte SA, Chamberlain D, et al. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol 2002; 158:563-575.
39. Naga Prasad SV, Jayatilleke A, Madamanchi A, et al. Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat Cell Biol 2005; 7:785-796.
40. Perrino C, Naga Prasad SV, Patel M, et al. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol 2005; 45:1862-70.